This article covers the highlights from the world of cancer investing, in particular, with the goal of helping you pick out the most important news of the week.
Veteran biotechnology analyst Michael King of JMP Securities has seen drug development evolve from hit-or-miss to the sophisticated, high-throughput discovery techniques in place today. He
Karyopharm Therapeutics (KPTI) is a clinical-stage pharmaceutical company founded in December 2008 by Dr. Sharon Shacham. One of the target markets if multiple myeloma, a $3.2 billion
Company chart and information is provided by TradingView based on 15-minute-delayed data.
Karyopharm Therapeutics Inc is a pharmaceutical company. The company focused on the discovery, development, and commercialization of medicines with the goal of improving the lives of patients with cancer.
| Website: | www.karyopharm.com |
| Email: | ikarp@karyopharm.com |
| Main Phone: | +1 617 658-0600 |
| Address: | 85 Wells Avenue |
| Address 2: | 2nd Floor |
| State: | MA |
| City / Town: | Newton |
| Country: | US |
| Postal Code: | 02459 |
| Exchange: | NGS |
| CEO: | Michael G. Kauffman |
| Employees: | 432 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
This article covers the highlights from the world of cancer investing, in particular, with the goal of helping you pick out the most important news of the week.
Veteran biotechnology analyst Michael King of JMP Securities has seen drug development evolve from hit-or-miss to the sophisticated, high-throughput discovery techniques in place today. He
Karyopharm Therapeutics (KPTI) is a clinical-stage pharmaceutical company founded in December 2008 by Dr. Sharon Shacham. One of the target markets if multiple myeloma, a $3.2 billion
Teen apparel and accessory retailer rue21, Inc. (RUE) said Thursday that it has entered into a definitive agreement to be acquired by private equity firm Apax Partners for approximately $1.1
| Last Price N/A | Change $ N/A | Change % N/A | Tick N/A |
| Bid N/A | Bid Size N/A | Ask N/A | Ask Size N/A |
| Open N/A | High N/A | Low N/A | Prev Close N/A |
| Last Trade | Volume N/A | 52 Wk Hi N/A | 52 Wk Low N/A |
| Market Cap N/A | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares N/A | EPS (TTM) N/A | PE Ratio N/A | Exchange N/A |
© 2022 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
